OncoTherapy Science Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	-823	-813	-1,285	-1,116	-2,570	-1,560
Depreciation & Amortization	-	-	-	-	16	49
Loss (Gain) From Sale of Assets	60	-	154	21	547	10
Other Operating Activities	1	-2	-2	-17	-3	-3
Change in Accounts Receivable	-2	-63	87	276	-247	-123
Change in Inventory	98	-4	25	131	-189	-16
Change in Accounts Payable	-75	21	-158	-240	385	-39
Change in Other Net Operating Assets	-21	46	-48	151	-12	-80
Operating Cash Flow	-762	-815	-1,227	-794	-2,073	-1,762
Capital Expenditures	-60	-	-2	-4	-456	-43
Other Investing Activities	-	-	-31	-16	-11	-9
Investing Cash Flow	-60	-	-33	-20	-467	-52
Issuance of Common Stock	1,456	1,178	676	-	1,478	-
Repurchase of Common Stock	-1	-1	-	-	-	-
Other Financing Activities	-56	-56	-5	95	-	-
Financing Cash Flow	1,399	1,121	671	95	1,478	-
Net Cash Flow	577	306	-589	-719	-1,062	-1,814
Free Cash Flow	-822	-815	-1,229	-798	-2,529	-1,805
Free Cash Flow Margin	-85.98%	-108.67%	-201.47%	-70.37%	-219.34%	-543.67%
Free Cash Flow Per Share	-2.90	-3.12	-5.78	-4.14	-13.49	-10.24
Cash Interest Paid	1	1	-	-	-	-
Cash Income Tax Paid	2	2	2	2	2	2
Levered Free Cash Flow	-537.38	-512.75	-937	-231.88	-1,782	-1,196
Unlevered Free Cash Flow	-536.75	-512.13	-937	-231.88	-1,782	-1,196
Change in Working Capital	-	-	-94	318	-63	-258

Source: S&P Global Market Intelligence. Standard template. Financial Sources.